Jaydess (Levonorgestrel)

Levonorgestrel released from the device binds to progesterone receptors in the endometrium, cervical mucus, and the hypothalamic‑pituitary axis. This suppresses ovulation, thickens cervical mucus to block sperm entry, and induces endometrial changes that reduce the chance of implantation.

The dosage of Jaydess is fixed at 13.5 mg of levonorgestrel released continuously from the intrauterine system. The exact regimen, including insertion timing and follow‑up, is determined by the prescribing healthcare professional based on individual patient needs.

Jaydess is intended for use in women who are not pregnant. It must be inserted after confirming the absence of pregnancy. While it can be used by breastfeeding mothers, the hormone levels are low and generally considered compatible with lactation, but clinicians should assess each case individually.

To order Jaydess, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with oral progestin pills, Jaydess offers continuous hormone delivery without daily dosing, leading to higher typical‑use effectiveness and improved compliance. Unlike higher‑dose intrauterine systems such as Mirena, Jaydess contains a lower levonorgestrel amount (13.5 mg) and is approved for up to three years of use, making it suitable for women seeking a lower‑dose option.

Jaydess should be stored at room temperature, below 25 °C, in its original sealed packaging. It must be protected from moisture and direct sunlight. The device should be kept out of reach of children and handled only by trained healthcare professionals during insertion.

Jaydess is inserted by a qualified healthcare provider into the uterine cavity through the cervical canal using a specialized inserter. The procedure is performed in a clinical setting under aseptic conditions. Once placed, the device remains in situ for up to three years, after which it can be removed or replaced.

Serious risks, although rare, include uterine perforation during insertion, device expulsion or displacement, pelvic inflammatory disease, and ectopic pregnancy if contraceptive failure occurs. Patients should be instructed to seek immediate medical attention for severe abdominal pain, abnormal bleeding, or signs of infection.

Jaydess is contraindicated in women who are currently pregnant, have active pelvic infection, known or suspected uterine anomalies that could impede placement, or a documented hypersensitivity to levonorgestrel or any component of the device. It should also be avoided in patients with a history of breast cancer or severe liver disease.